| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Vnus Medical Technologies, Inc. |
| 238 East Caribbean Drive, Sunnyvale, CA 94089 * (408) 747-1200 |
| Business Description | The company develops, manufactures and markets the Closure system, a proprietary system of products targeted at the minimally invasive treatment of venous reflux disease. |
|
Filing Information Not yet | |||
| To Trade As | VNUS (NASNTL) | Industry | Manufacturing (SIC 3845) |
| Type of Stock Offered | Common Shares | Filing Date | 8/18/00 |
| Domestic Shares Filed | 4,250,000 | Filing Range | $11.00 - $13.00 |
| Foreign Shares Filed | 0 | Offering Amount | $51,000,000 |
| Company Shares | 4,250,000 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | 14,486,767 |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| U.S. Bancorp Piper Jaffray | Lead Manager | (612) 342-6220 |
| Chase H&Q; | Co-manager | (415) 439-3626 |
| Dain Rauscher Wessels | Co-manager | (612) 371-2818 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 6 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | 6/30/99 | 6/30/00 | ||
| Revenues | - | - | 0.000 | 0.168 | 0.483 | 0.228 | 0.717 |
| Income from Oper. | - | - | - | - | - | - | - |
| Net Income | - | - | -3.936 | -5.107 | -6.244 | -2.857 | -3.942 |
| E.P.S | - | - | -1.510 | -1.750 | -1.840 | -0.860 | -1.020 |
| Revenue Growth (%) | - | - | - | 187.500 | 214.47 | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -5.98 | -3.09 | -2.88 | ||||
| Cash Flow - Inv. | -0.24 | -0.06 | -0.10 | ||||
| Cash Flow - Fin. | 15.70 | 15.96 | -0.42 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 6/30/00 | Financial Ratios | ||||
| Total Assets | 9.01 | Current Assets | 8.68 | Current Ratio | 7.40 |
| Total Liab. | 1.35 | Current Liab. | 1.17 | Debt Ratio | 14.97% |
| Total Equity | 7.66 | Working Cap. | 7.50 | Debt to Equity Ratio | 0.18 |
| Cash | 7.52 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for the expansion of sales, marketing and reimbursement activities; expansion of manufacturing capacity; clinical research and product development; capital expenditures; repayment of debt, and working capital and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Latham & Watkins |
| Bank's Law Firm | Dewey Ballantine |
| Registrar/Transfer Agent | U. S. Stock Transfer Corporation |
| Auditor | Arthur Andersen |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Menlo Ventures affiliated entities | 45.30 | |
| Sprout Group affiliated entities | 22.00 | |
| State of Michigan, The | 10.30 | |
| Bay City Capital | 10.30 | |
| BankAmerica Ventures affiliated entities | 8.40 | |
| Note: represents ownership of 5% or more prior to the offering. | ||